Scroll Up
Scroll Down
Play Play Play Play
Unregistered User
Click here if this is not your Personal Edition
 
Contact Us | Free E-Mail Updates | Journals | Register a colleague
 
 
Asthma
 
   
 
SEARCH   
Doctor's Guide Free CME
Medline
Congress Resource Centre
 

 EXPLORE :
   Most Read News
 All News  All News
 All Webcasts / CME  All Webcasts / CME
 All Cases  All Cases
 Congress Resource Centre  Congress Resource Centre
 All Medical Resources  All Medical Resources
 Medical  My Personal Edition



Warning | Privacy

 

 
 Recent news - Asthma
    TopAbstracts in Asthma 12/01/2008 - (DGNews)
    TopAbstracts in Asthma 11/24/2008 - (DGNews)
    TopAbstracts in Asthma 11/17/2008 - (DGNews)
    ERRATUM: Pretreatment With Omalizumab Can Safely Increase Effectiveness of Immunotherapy: Presented at ACAAI - (DGDispatch)
    Antibodies to Cockroach, Mouse Proteins Associated With Asthma and Allergies in Preschool Children - (DGNews)

    News archive

     Recent webcasts/CME - Asthma
    Asthma Treatment Guidelines and Use of Inhalers
    New Guidelines for the Diagnosis and Management of Asthma
    Obesity and Pulmonary Dysfunction

    Webcasts/CME archive

     Recent cases - Asthma
      Glucocorticoid Hypersensitivity as a Rare but Potentially Fatal Side Effect of Paediatric Asthma Treatment: A Case Report
      A Case of Lactic Acidosis Complicating Assessment and Management of Asthma
      Role of Vasopressin in the Treatment of Anaphylactic Shock in a Child Undergoing Surgery for Congenital Heart Disease: A Case Report
      Isolated Left Lung Aplasia with Bronchial Asthma
      Two Cases of Asthma in Handicapped Elderly Persons in which Assisted Inhalation Therapy was Effective

      Cases archive
        




      my personal edition > asthma > news
      divider

        E-Mail this DGDispatch to a colleague

      DGDispatch


      Budesonide/Formoterol by Metered-Dose Inhaler Appears Safe in Children With Asthma: Presented at ATS

      By Marvin Ross

      TORONTO -- May 26, 2008 -- Budesonide/formoterol pressurised metered-dose inhaler (MDI) is well tolerated as a treatment for children with persistent, mild to moderate asthma, and its safety profile is similar to that of budesonide and formoterol, according to a 12-week, randomised trial.

      The study was presented here on May 20 at the 104th International Conference of the American Thoracic Society (ATS).

      David S. Pearlman, MD, Clinical Researcher, Colorado Allergy and Asthma Centers, Denver, Colorado, and colleagues enrolled 411 children aged 6 to 15 years with asthma.

      Patients participated in a 2-week run-in phase during which their asthma medications (inhaled corticosteroids) were discontinued and they were given 2 inhalations of budesonide 40 mcg BID by pressured MDI.

      Researchers then randomised 128 children to receive budesonide/formoterol 40/4.5 mcg 2 inhalations BID, 145 children to receive budesonide 40 mcg 2 inhalations BID, and 138 children to receive formoterol 4.5 mcg 2 inhalations BID.

      Patients were evaluated for adverse events, clinical chemistry, and vital signs and underwent electrocardiograms. Adverse events were recorded by the caregivers in paper diaries and were reviewed by the investigators. Asthma symptoms or signs were considered adverse events if they were new to the patient, were serious, were not consistent with the patient's pre-existing asthma history, or led to discontinuation.

      All treatments were well tolerated; most adverse events were of mild or moderate intensity. Adverse events were reported by 70.3% of the budesonide/formoterol group, 63.4% of the budesonide group, and 70.3% of the formoterol patients.

      Drug-related adverse events were reported by 3.1% of budesonide/formoterol patients, 3.4% of budesonide patients, and 6.5% of formoterol patients. These events included asthma, headache, insomnia, cough, and psychomotor hyperactivity.

      Mean changes in serum glucose levels and serum potassium levels from baseline to treatment maximum in the budesonide/formoterol patients compared with budesonide were statistically significant (P < .05 and P < .01, respectively). The researchers stated that both these changes were small and were not considered to be clinically meaningful.

      Mean changes in heart rate from baseline were small and not clinically meaningful, according to the researchers. The percentages of patients with heart rate values that were normal at baseline and then crossed the high threshold (>=100 BPM) at treatment maximum were higher for the budesonide/formoterol (11.7%) and formoterol (8.7%) groups compared with the budesonide group (3.4%).

      No clinically meaningful differences were observed among groups for vital signs and/or physical examinations.

      Budesonide/formoterol pressured MDI was well tolerated in this group of patients and had a safety profile similar to that of budesonide or formoterol alone, the researchers concluded.


      [Presentation title: Safety of Budesonide/Formoterol Pressurized Metered-Dose Inhaler (Budesonide/Formoterol pMDI) in Children With Asthma Previously Treated With Inhaled Corticosteroids (ICSs). Poster K67]



      E-Mail this DGDispatch to a colleague   To print, use this version






      All contents Copyright (c) 1995-2008 Doctor's Guide Publishing Limited. All rights reserved.



      The NTK initiative. Physicians helping physicians identify Need-To-Know science
         Feedback
      Please rate this article: Strongly DISAGREE...Strongly AGREE NTK logo
      Question 1 - Physicians need to become aware of this information as soon as possible. Question 2 - This information is likely to have an impact on the way physicians practice medicine.
      1
      2
      3
      4
      5
      6
      7
      Send